Clinical Case Database / Category: Clinical Care

Bladder outflow obstruction

Publication details

Gurmukh Sandhu (FY1), Matthew Morgan (FY2), Daniel Wilby BM MRCS(Eng), Shamim Khan OBE FRCS (Urol) FEBU
Foundation Years Journal, volume 3, issue 5, p.9 (123Doc Education, London, June 2009)

Abstract

Mr X, a 54-year-old gentleman is referred by his GP to the urology FY2 on call with a 24-hour history of being unable to pass urine and increasing suprapubic abdominal pain. A working diagnosis of acute urinary retention is made.

Access the Clinical Cases Database

A subscription is required to read the full article. Please subscribe using one of the options below.

Authors

Gurmukh Sandhu (FY1)

Department of Urology
Guys Hospital
London
SE1 9RT

Matthew Morgan (FY2)

Department of Urology
Guys Hospital
London
SE1 9RT

Daniel Wilby BM MRCS(Eng)

Clinical Fellow
Department of Urology
Guys Hospital
London, SE1 9RT

Shamim Khan OBE FRCS (Urol) FEBU

Consultant Urological Surgeon
Department of Urology
Guys Hospital
London, SE1 9RT

References

1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the epic study. Eur Urol, 2006, 50:1306–1315.
2. Dawson C, Whitfield H. ABC of Urology: Bladder Outflow Obstruction. BMJ, 1996, 312:767–770.
3. Trueman P, Hood SC, Nayak USL, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed "benign prostatic hyperplasia" and their effect on quality of life in a community-based survey of men in the UK. BJU Int, 1999, 83:410–415.
4. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA, 1993, 270:860–864.
5. Abrams, P; Bruskewitz, R; De La Rosette, J, et al. The diagnosis of bladder outlet obstruction: urodynamics. In: ATK Cockett,S Khoury, Y Aso, et al. (eds) Proceedings, the 3rd International Consultation on BPH. World Health Organization, 1995. pp. 299–367.
6. Victor W, Nitti MD. Pressure Flow Urodynamic Studies: The Gold Standard for Diagnosing Bladder Outlet Obstruction. Rev Urol, 2005, 7(Suppl 6): S14–S21.
7. Lowe F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate cancer and prostate diseases, 199, 2:110–119.
8. McConnell et al. The long term effect of doxazocin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl J Med, 2003, 349:2387–2398.
9. Reynard et al. Oxford handbook of Urology. 2006 Oxford university Press.
10. McConnell et al. The effect of finasteride on the risk of AUR and the need for surgical treatment among men with BPH (PLESS). N Eng J Med, 1998, 338:557–563.
11. Anderson et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo controlled study. The Scandinavian BPH Study Group. Urology, 1995, 46:631–637.
12. Foley et al. Finasteride for haematuria due to BPH. A prospective study of the natural history of haematuria associated with BPH and the effect of finasteride. J Urol, 2000, 163:496–498.
13. ReynardJ. Does anti-cholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone of in combination with other agents? Current opinions in Urology, 2004, 14:13–16.
14. McNeil A. The Role of Alpha-Blockers in the Management of Acute Urinary Retention Caused by Benign Prostatic Obstruction. European Urology, 2004, 45(3):325–332.
15. Baazeem and Elhilali. Surgical management of benign prostatic hyperplasia: current evidence. Nature clinical practice, 2008, 5(10):540–546.
16. Mundy AR. Mangement of Urethral Strictures. Postgrad Med J. 2006; 82: 489 – 493.
17. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA, 1993, 270:860–864.
18. Lowe F. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate cancer and prostate diseases, 199, 2:110-2119.
19. Reynard et al. Oxford handbook of Urology. 2006, Oxford university Press.
20. McConnell et al. The long-term effect of doxazocin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. New Engl J Med, 2003, 349:2387–2398.
21. McConnell et al. The effect of finasteride on the risk of AUR and the need for surgical treatment among men with BPH (PLESS). N Eng J Med, 1998, 338:557-563.
22. Anderson et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo controlled study. The Scandinavian BPH Study Group. Urology, 1995, 46:631–637.
23. Foley et al. Finasteride for haematuria due to BPH. A prospective study of the natural history of haematuria associated with BPH and the effect of finasteride. J Urol, 2000, 163:496–498.
24. Baazeem and Elhilali. Surgical management of benign prostatic hyperplasia: current evidence. Nature clinical practice, 2008, 5(10):540–546.

Disclaimers

Conflict Of Interest

The Journal requires that authors disclose any potential conflict of interest that they may have. This is clearly stated in the Journal’s published “Guidelines for Authors”. The Journal follows the Guidelines against Conflict of Interest published in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/urm_full.pdf).

Financial Statement

The authors of this article have not been paid. The Journal is financed by subscriptions and advertising. The Journal does not receive money from any other sources. The decision to accept or refuse this article for publication was free from financial considerations and was solely the responsibility of the Editorial Panel and Editor-in-Chief.

Patient Consent statement

All pictures and investigations shown in this article are shown with the patients’ consent. We require Authors to maintain patients’ anonymity and to obtain consent to report investigations and pictures involving human subjects when anonymity may be compromised. The Journal follows the Guidelines of the Uniform Requirements for Manuscripts (http://www.icmje.org/urm_full.pdf). The Journal requires in its Guidelines for Authors a statement from Authors that “the subject gave informed consent”.

Animal & Human Rights

When reporting experiments on human subjects, the Journal requires authors to indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the HelsinkiDeclaration of 1975, as revised in 2008.

About the Clinical Cases Database

T​he Foundation Years Clinical Cases Database is​ a selection of 600 peer-reviewed clinical cases in the field of patient safety and clinical practice, specifically focused on the clinical information needs of junior doctors, based around the Foundation Year Curriculum programme (MMC). The cases have been chosen to align with the Foundation Year Curriculum.

The database is fully searchable, or can be browsed by medical specialty. Abstracts can be read free of charge, however a subscription is required in order to read the complete cases.